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ABSTRACT - A double blind balanced Latin-square study was conducted on 20 adult patients with 
decompensated bladders to determine the relative effectiveness of oral and parenteral bethanechol 
chloride (Urecholine) on the stretch response of bladder muscle. Detrusor reaction was measured by 
modified cystometry. Five mg. of subcutaneous bethanechol chloride produced a significant increase 
in intravesical pressure which was more rapid in onset, of larger magnitude, and of shorter duration 
than oral doses of 100 and 200 mg. 
Because of the relative paucity of data in the 
literature documenting the efficacy of oral 
bethanechol (Urecholine) in stimulating the 
urinary bladder’ and since the cholinergic agent 
is employed so widely, it was deemed of 
interest to conduct a double blind randomized 
study on a group of patients with partial or com- 
plete urinary retention. 
Material and Methods 
Twenty patients ranging in age from eighteen 
to eighty-five years and including 11 females, 
were selected as subjects. Eight individuals 
were able to urinate but with postvoiding 
residual urine volumes greater than 100 ml. The 
remaining 12 people required catheter drainage 
because of complete retention; 8 males were on 
cystostomy tubes, 1 on intermittent catheteriza- 
tion, and 4 females on inlying urethral catheter. 
The patients were subjected to a series of 
modified cystometric studies, each having one 
set of cystometrographs daily for five days. Prior 
to the cystometric run the patient received one 
of five combinations of oral and subcutaneous 
doses of bethanechol which were unknown at 
the time of administration (Table I). The 5 mg. 
and the placebo subcutaneous doses were con- 
tained in similar l-ml. ampules while the 
placebo, 50 mg., 100 mg., and 200 mg., oral 
doses were incorporated in identical appearing 
tablets. 
TABLE I. Combinations of oral and 
subcutaneous doses 
Treatment Route 
Day Oral Subcutaneous 
1 Placebo 
2 Urecholine 50 mg. 
3 Urecholine 100 mg. 








The Merrill gas cystometer was utilized in 
the study. The bladder was filled with air at a 
rate of 100 ml. per minute. A continuous re- 
cording of intravesical pressure was obtained 
to 100 ml. of bladder capacity. The test dose 
by the oral and subcutaneous route was then 
administered and the cystometric study re- 
peated at ten, twenty, thirty, forty-five, and 
one hundred twenty minutes. The temperature, 
pulse rate, respiratory rate, blood pressure, 
skin color, moisture, pupil diameter, peristaltic 
activity, and bowel movements were recorded 
before and throughout the period of study. The 
anticholinergic agent, atropine sulfate, was 
available at all times for any side effects. 
The intravesical pressure observed at lOO-ml. 
bladder volume during the control cystometro- 
graph prior to administration of the test medica- 
tion was considered as the base line value. The 





response of the detrusor to the various drug 
combinations was determined from the intra- 
vesical pressure at lOO-ml. volume noted at ten, 
twenty, thirty, forty-five, ninety, and one 
hundred twenty minutes after administration of 
a particular medication. The mean of all the 
intravesical pressures at the various time inter- 
vals for each test done was computed, tabu- 
lated, and plotted in a graph. 
Results and Comment 
Although 20 patients were started on the 
study, only 17 were subjected to the entire five 
sets of unknown combinations of bethanechol 
and placebo. Three patients could not tolerate 
the oral 200-mg. dose of bethanechol, and thus 
their sets of cystometrographs were incomplete. 
The mean intravesical pressure changes 
occurring after administration of the various 
doses of bethanechol are depicted in Figure 1. 
It will be observed that the 5-mg. subcutaneous 
dose stimulated a more rapid response of the 
detrusor than did the oral doses of 50, 100, and 
200 mg. Parenteral bethanechol produced a 
significant intravesical pressure rise within ten 
minutes after injection, the peak effect at thirty 
minutes, and complete subsidence within one 
hundred twenty minutes. 
Ingested bethanechol failed to produce a 
perceptible response of the detrusor muscle at the 
50-mg. dose level but did elicit significant in- 
creases in intravesical pressure with greater 
drug quantities. When bethanechol is taken 
per OS, it will be observed in Figure 1 that the 
cholinergic agent is slower to act than the 
subcutaneous dose but maintains its effective- 
ness for a longer period of time than the 
parenteral medication. 
A mild degree of sweating was observed in 9 
patients receiving 200 mg., 1 patient with 100 
mg., and 5 patients administered 5 mg. sub- 
cutaneously. Profuse sweating was noted in 1 
patient who received 200 mg. and 1 patient 
who received 5 mg. subcutaneously. Diarrhea 
developed in 1 patient after the 200-mg. session 
was completed. With the same dose, 2 patients 
felt cold and chilly, and in I patient bradycardia 
and hypotension developed. 
Four patients received atropine after 200 
mg. of bethanechol orally. Two patients re- 
ceived the anticholinergic drug after the forty- 
five-minute cystometry, while 2 patients were 
given atropine at the conclusion of the session. 
The present balanced Latin-square, con- 
trolled dose response study to determine the 
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FIGURE 1. Composite graph of mean intravesical 
pressure at 100-ml. volume before and at various 
times after bethanechol administration. 
oral dose of bethanechol that is clinically 
equivalent to 5 mg. of the drug administered 
subcutaneously, is entirely in accord with a 
similar investigation reported previously.’ Be- 
cause of the prolonged action of ingested 
bethanechol and the possibility of cumulative 
effect with frequent repeated oral administra- 
tion, it would be safest to use oral bethanechol 
in doses less than 100 mg. given every four to 
six hours. If one desires to use larger doses, the 
patient should be hospitalized where strict 
surveillance can be obtained. 
Our observations reaffirm the fact that the de- 
trusor stimulation by parenteral bethanechol is 
dissipated completely within two hours after 
injection; and thus subcutaneous injections can 
be repeated at three-hour intervals without con- 
cern about cumulative responses. 
We should like to emphasize that this study 
evaluated the localized stretch response of 
bladder muscle to oral and parenteral bethane- 
chol administration and not the ability of the 
bladder to empty itself. Although 50 mg. of 
oral bethanechol caused little change in intra- 
vesical pressure, this dosage has been found to 
be very effective clinically in the rehabilitation 
of decompensated bladders.293 
Ann Arbor, Michigan 48109 
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